PharmaDrug Inc CEO Daniel Cohen tells Proactive it has entered into a sponsored research collaboration with the Terasaki Institute for Biomedical Innovation to work on an ocular psychedelic drug delivery platform.
Cohen says the Terasaki Institute, a biotechnology lab that develops medical devices protocols for a variety of diagnostic, monitoring and treatment applications, will develop the platform to transmit tryptamine-based pharmaceuticals such as DMT to treat eye diseases like glaucoma, which is the second-leading cause of blindness in the world.